LPCN: Lipocine Inc. Company Short-Term Debt

Symbol and logo of brand Lipocine Inc. (LPCN)

Lipocine Inc. revenues are based on the commercialization of metabolic therapies and the implementation of oral treatments for MASH. Adjustments to short-term loan amounts allow for the agile management of refinancing risks, with the indicator fixed at 0.00. The growth strategy relies on the LIPPRO platform to replace injections, while research efficiency is enhanced through the implementation of robotic laboratory complexes.

LPCN (Lipocine Inc) Company Short-Term Debts history from 07/04/2022 to 10/30/2026

LPCN (Lipocine Corporation): analytical breakdowns and indicator data

- current quotes and average value forecast:
Price Chart Lipocine|LPCN - Fair Value Consensus
- market capitalization information:
Market Value Lipocine Inc.|LPCN - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Lipocine|LPCN - Book Capitalization|Market Cap to Net Assets Ratio lipocine.com|LPCN - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Lipocine Inc.|LPCN - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Lipocine Inc.|LPCN - Company Cumulative Debt|Debt to Book Value Lipocine Inc.|LPCN - Amount of Long-Term Liabilities|Company Short-Term Debts Lipocine|Quick Ratio lipocine.com
- net income and valuation multiples indicators:
LPCN - Company Net Income
Basic company analysis:Lipocine - LPCN
Mass-produced product of Lipocine Corporation

This indicator measures total liabilities with maturities of up to one year, allowing investors to assess refinancing risks and balance sheet liquidity. By analyzing the volume of short-term debt capital, it becomes evident how the debt load becomes critical for Lipocine Inc. (LPCN) during periods of FDA regulatory delays, when investment outflows complicate the servicing of current loans during the development of endocrine drugs.

Who Lipocine Inc. competes with

ASND - Company Short-Term Debt|Company Short-Term Loans and Borrowings MDGL (Madrigal Pharmaceuticals Inc)|Corcept (CORT) - Company Short-Term Debt|Company Current Liabilities Rhythm Corp|AKRO (Akero Therapeutics) - Company Short-Term Debts|Company Short-Term Debts metsera.com|Company Current Liabilities MLTX (MoonLake)|CRNX (Crinetics Pharmaceuticals, Inc.) - Company Short-Term Loans and Borrowings|Company Short-Term Debt NewAmsterdam Pharma N.V. NAMS|SLNO - Company Current Liabilities|Amicus Therapeutics - Company Short-Term Debts|Short-Term Debt 89bio.com|AGIO (Agios Pharmaceuticals, Inc.) - Company Current Liabilities|GPCR: Amount of Current Liabilities|MDXG (MiMedx Group) - Company Short-Term Debts|Company Short-Term Debts Rezolute Bio|Company Short-Term Debts LXRX|Company Short-Term Debt MBX (mbxbio.com)|Company Short-Term Debt Altimmune ALT|Aardvark Therapeutics Inc. (AARD) - Short-Term Debt|SGMT - Company Short-Term Debt|BIOA: Company Short-Term Debt|BMEA: Company Short-Term Debts|QNCX - Short-Term Debt Volume|Company Short-Term Debt Fractyl Health|vTv Therapeutics Inc (VTVT) - Short-Term Debt Volume|Company Short-Term Debt Agape ATP Corporation (ATPC)|Company Current Liabilities pluri-biotech.com PLUR|Company Short-Term Debt Synlogic SYBX|Matinas BioPharma Holdings, Inc. - Company Short-Term Debt|Spruce Biosciences - Company Short-Term Debts|Short-Term Debt Volume Galecto Inc GLTO|Carmell Corp (CTCX) - Company Short-Term Debt|Current Liabilities LUMO (Lumos Therapeutics)|Company Short-Term Debt Organovo Holdings, Inc.|Short-Term Debt radiuspharm.com RDUS